Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable?

BMC Psychiatry

Volumn 12, Issue , 2012, Pages

  Bramness, Jørgen G ^a   Gundersen, Øystein H ^a   Guterstam, Joar ^b   Rognli, Eline B ^a   Konstenius, Maija ^b   Løberg, Else Marie ^c   Medhus, Sigrid ^a   Tanum, Lars ^a   Franck, Johan ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Amphetamine; Drug induced psychosis; Methamphetamine; Primary psychotic disorder; Schizophrenia

Indexed keywords

AMPHETAMINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; OPIATE; METHAMPHETAMINE;

AMPHETAMINE INDUCED PSYCHOSIS; ARTICLE; AUDITORY HALLUCINATION; BODY TEMPERATURE; CLINICAL FEATURE; DOPAMINERGIC NERVE CELL; DRUG INDUCED DISEASE; HEART RATE; HUMAN; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SEROTONINERGIC NERVE CELL; SUBSTANCE ABUSE; THINKING IMPAIRMENT; ACUTE PSYCHOSIS; CHRONIC PSYCHOSIS; DISEASE COURSE; GENETIC SUSCEPTIBILITY; POPULATION; PREVALENCE; SCHIZOPHRENIA SPECTRUM DISORDER;

AMPHETAMINE; DIAGNOSIS, DIFFERENTIAL; DISEASE SUSCEPTIBILITY; HUMANS; METHAMPHETAMINE; MODELS, PSYCHOLOGICAL; PSYCHOSES, SUBSTANCE-INDUCED; RISK FACTORS; SCHIZOPHRENIA;

EID: 84870316254     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-12-221     Document Type: Article

References (108)

1. Lineberry TW, Bostwick JM. Methamphetamine abuse: a perfect storm of complications. Mayo Clin Proc 2006, 81(1):77-84. 10.4065/81.1.77, 16438482.
2. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 1993, 33:639-677. 10.1146/annurev.pa.33.040193.003231, 8494354.
3. Robinson TE, Berridge KC. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 2000, 95(Suppl 2):S91-S117.
4. Degenhardt L, Roxburgh A, McKetin R. Hospital separations for cannabis- and methamphetamine-related psychotic episodes in Australia. Med J Aust 2007, 186(7):342-345.
5. Degenhardt L, Roxburgh A, Black E, Bruno R, Campbell G, Kinner S, et al. The epidemiology of methamphetamine use and harm in Australia. Drug Alcohol Rev 2008, 27(3):243-252. 10.1080/09595230801950572, 18368605.
6. Durell TM, Kroutil LA, Crits-Christoph P, Barchha N, Van Brunt DL. Prevalence of nonmedical methamphetamine use in the United States. Subst Abuse Treat Prev Policy 2008, 3:19. 10.1186/1747-597X-3-19, 2515829, 18655714.
7. Maxwell JC, Rutkowski BA. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007. Drug Alcohol Rev 2008, 27(3):229-235. 10.1080/09595230801919460, 18368603.
8. McKetin R, Kozel N, Douglas J, Ali R, Vicknasingam B, Lund J, et al. The rise of methamphetamine in Southeast and East Asia. Drug Alcohol Rev 2008, 27(3):220-228. 10.1080/09595230801923710, 18368602.
9. Odegård Lund M, Skretting A, Lund K. Rusmiddelbruk blant unge voksne, 21-30 år 2007, Oslo: Statens Institutt for Rusmiddelforskning.
10. Gonzales R, Ang A, McCann MJ, Rawson RA. An emerging problem: methamphetamine abuse among treatment seeking youth. Subst Abus 2008, 29(2):71-80.
11. Katz G, Durst R, Shufman E, Bar-Hamburger R, Grunhaus L. Substance abuse in hospitalized psychiatric patients. Isr Med Assoc J 2008, 10(10):672-675.
12. Mordal J, Bramness JG, Holm B, Morland J. Drugs of abuse among acute psychiatric and medical admissions: laboratory based identification of prevalence and drug influence. Gen Hosp Psychiatry 2008, 30(1):55-60. 10.1016/j.genhosppsych.2007.10.006, 18164941.
13. Cantor-Graae E, Nordstrøm LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 2001, 48(1):69-82. 10.1016/S0920-9964(00)00114-6, 11278155.
14. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264(19):2511-2518. 10.1001/jama.1990.03450190043026, 2232018.
15. Ringen PA, Melle I, Birkenaes AB, Engh JA, Faerden A, Vaskinn A, et al. The level of illicit drug use is related to symptoms and premorbid functioning in severe mental illness. Acta Psychiatr Scand 2008, 118(4):297-304. 10.1111/j.1600-0447.2008.01244.x, 18759810.
16. Ringen PA, Lagerberg TV, Birkenaes AB, Engn J, Faerden A, Jonsdottir H, et al. Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder. Psychol Med 2008, 38(9):1241-1249.
17. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001, 50(2):71-83. 10.1016/S0006-3223(01)01134-9, 2913410, 11526998.
18. Chambers RA, Sentir AM, Engleman EA. Ventral and dorsal striatal dopamine efflux and behavior in rats with simple vs. co-morbid histories of cocaine sensitization and neonatal ventral hippocampal lesions. Psychopharmacology (Berl) 2010, 212(1):73-83.
19. Paparelli A, Di FM, Morrison PD, Murray RM. Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front Behav Neurosci 2011, 5:1. 3024828, 21267359.
20. Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis-preliminary observations. Biol Psychiatry 1970, 2(2):95-107.
21. Bell DS. The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry 1973, 29(1):35-40. 10.1001/archpsyc.1973.04200010020003, 4711131.
22. Griffith JJ, Oates J, Cavanaugh J. Paranoid episodes induced by drugs. JAMA 1968, 205:36.
23. Janowsky DS, Risch C. Amphetamine psychosis and psychotic symptoms. Psychopharmacology (Berl) 1979, 65(1):73-77.
24. Espelin DE, Done AK. Chlorpromazine vs. amphetamine. N Engl J Med 1968, 279(6):329.
25. Calello DP, Osterhoudt KC. Acute psychosis associated with therapeutic use of dextroamphetamine. Pediatrics 2004, 113(5):1466.
26. Lucas AR, Weiss M. Methylphenidate hallucinosis. JAMA 1971, 217(8):1079-1081. 10.1001/jama.1971.03190080041008, 5109429.
27. Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2006, 163(7):1149-1152. 10.1176/appi.ajp.163.7.1149, 16816217.
28. Spear J, Alderton D. Psychosis associated with prescribed dexamphetamine use. Aust N Z J Psychiatry 2003, 37(3):383.
29. Surles LK, May HJ, Garry JP. Adderall-induced psychosis in an adolescent. J Am Board Fam Pract 2002, 15(6):498-500.
30. Young D, Serorille WB. Paranoid psychosis in narcolepsy and possible dangers of benzedrine treatment. Med Clin North Am 1938, 22(637):643.
31. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R. Clinical course and outcomes of methamphetamine-dependent adults with psychosis. J Subst Abuse Treat 2008, 35(4):445-450. 10.1016/j.jsat.2007.12.004, 18294802.
32. Grant KM, Levan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, et al. Methamphetamine-Associated Psychosis. J Neuroimmune Pharmacol 2011, 7(1):113-139. 3280383, 21728034.
33. Leamon MH, Flower K, Salo RE, Nordahl TE, Kranzler HR, Galloway GP. Methamphetamine and paranoia: the methamphetamine experience questionnaire. Am J Addict 2010, 19(2):155-168. 10.1111/j.1521-0391.2009.00014.x, 3168774, 20163388.
34. McKetin R, McLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006, 101(10):1473-1478. 10.1111/j.1360-0443.2006.01496.x, 16968349.
35. Shoptaw S, Peck J, Reback CJ, Rotheram-Fuller E. Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment. J Psychoactive Drugs 2003, 35(Suppl 1):161-168.
36. Wallace C, Galloway T, McKetin R, Kelly E, Leary J. Methamphetamine use, dependence and treatment access in rural and regional North Coast of New South Wales, Australia. Drug Alcohol Rev 2009, 28(6):592-599. 10.1111/j.1465-3362.2008.00016.x, 19930011.
37. Yen CF, Chong MY. Comorbid psychiatric disorders, sex, and methamphetamine use in adolescents: a case-control study. Compr Psychiatry 2006, 47(3):215-220. 10.1016/j.comppsych.2005.07.006, 16635651.
38. Mahoney JJ, Hawkins RY, De La Garza R, Kalechstein AD, Newton TF. Relationship between gender and psychotic symptoms in cocaine-dependent and methamphetamine-dependent participants. Gend Med 2010, 7(5):414-421. 10.1016/j.genm.2010.09.003, 3342664, 21056868.
39. Matsumoto T, Kamijo A, Miyakawa T, Endo K, Yabana T, Kishimoto H, et al. Methamphetamine in Japan: the consequences of methamphetamine abuse as a function of route of administration. Addiction 2002, 97(7):809-817. 10.1046/j.1360-0443.2002.00143.x, 12133119.
40. Grant KM, Kelley SS, Agrawal S, Meza JL, Meyer JR, Romberger DJ. Methamphetamine use in rural Midwesterners. Am J Addict 2007, 16(2):79-84. 10.1080/10550490601184159, 17453608.
41. Medhus S, Mordal J, Holm B, Mørland J, Bramness JG. A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wards. Psychiatry research 2012,
42. Sara G, Burgess P, Malhi G, Whiteford H. Amphetamine availability and admissions for psychosis in New South Wales, 2001-2009. Aust N Z J Psychiatry 2011, 45(4):317-324. 10.3109/00048674.2010.547455, 21303192.
43. Ujike H, Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci 2004, 1025:279-287. 10.1196/annals.1316.035, 15542728.
44. Vos PJ, Cloete KJ, Le RA, Kidd M, Jordaan GP. A retrospective review of trends and clinical characteristics of methamphetamine-related acute psychiatric admissions in a South African context. Afr J Psychiatry (Johannesbg ) 2010, 13(5):390-394.
45. de la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, Pichini S. Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. Clin Pharmacokinet 2004, 43(3):157-185. 10.2165/00003088-200443030-00002, 14871155.
46. Segal DS, Kuczenski R. An escalating dose "binge" model of amphetamine psychosis: behavioral and neurochemical characteristics. J Neurosci 1997, 17(7):2551-2566.
47. Semple SJ, Zians J, Grant I, Patterson TL. Impulsivity and methamphetamine use. J Subst Abuse Treat 2005, 29(2):85-93. 10.1016/j.jsat.2005.05.001, 16135337.
48. Semple SJ, Zians J, Strathdee SA, Patterson TL. Psychosocial and behavioral correlates of depressed mood among female methamphetamine users. J Psychoactive Drugs 2007, 4(Suppl):353-366.
49. Williamson S, Gossop M, Powis B, Griffiths P, Fountain J, Strang J. Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend 1997, 44(2-3):87-94.
50. Volkow Nora D, . NIDA Research Report Methamphetamine Abuse and Addiction 2006, Washington: National Institute on Drug Abuse, NIDA Research Report.
51. Medhus S, Mordal J, Holm B, Mørland J, Bramness JG. Symptoms and drug use among (meth)amphetamine positive patients admitted to the acute psychiatric ward. Psychiatr Res 2012, in press.
52. Harris D, Batki SL. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict 2000, 9(1):28-37. 10.1080/10550490050172209, 10914291.
53. Jonsson LE, Sjostrom K. A rating scale for evaluation of the clinical course and symptomatology in amphetamine psychosis. Br J Psychiatry 1970, 117(541):661-665. 10.1192/bjp.117.541.661, 5492176.
54. Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol 2003, 6(4):347-352. 10.1017/S1461145703003675, 14604449.
55. Yui K, Ikemoto S, Ishiguro T, Goto K. Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia. Ann N Y Acad Sci 2000, 914:1-12.
56. Srisurapanont M, Arunpongpaisal S, Wada K, Marsden J, Ali R, Kongsakon R. Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(4):959-964. 10.1016/j.pnpbp.2011.01.014, 21277930.
57. Bell DS. Comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry 1965, 111:701-707. 10.1192/bjp.111.477.701, 14337419.
58. Bousman CA, Glatt SJ, Everall IP, Tsuang MT. Methamphetamine-Associated Psychosis: A model for Biomarker Discovery in Schizofrenia. Handbook of Schizophrenia Spectrum Disorders Volume 1 2011, 327-343. Dordrecht: Springer Science+Business Media B.V, Ritsner MS.
59. Ellinwood EH. Amphetamine Psychosis: I. Description of the Individuals and Process. J Nerv Ment Dis 1967, 144(4):273-283.
60. Connell PH. Amphetamine Psychosis. Maudsley Monograph No. 5 1958, London: Oxford University Press.
61. McIver C, McGregor C, Baigent M, Spain D, Newcombe D, Ali R. Guidelines for the medical management of patients with methamphetamine-induced psychosis 2006, South Australia: Drug and Alcohol Services.
62. Slater E. Book Review of "Amphetamine Psychosis" by P. H. Connell. Br Med J 1959, 21:488.
63. Yeh HS, Lee YC, Sun HJ, Wan SR. Six months follow-up of patients with methamphetamine psychosis. Zhonghua Yi Xue Za Zhi (Taipei) 2001, 64(7):388-394.
64. Grelotti DJ, Kanayama G, Pope HG. Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy: presentation of a case and review of the literature. Am J Psychiatry 2010, 167(1):17-23. 10.1176/appi.ajp.2009.08111695, 20068123.
65. Yui K, Ishiguro T, Goto K, Ikemoto S. Susceptibility to subsequent episodes in spontaneous recurrence of methamphetamine psychosis. Ann N Y Acad Sci 2000, 914:292-302.
66. Akiyama K. Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence. Ann N Y Acad Sci 2006, 1074:125-134. 10.1196/annals.1369.012, 17105910.
67. Kittirattanapaiboon P, Mahatnirunkul S, Booncharoen H, Thummawomg P, Dumrongchai U, Chutha W. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug Alcohol Rev 2010, 29(4):456-461.
68. Yui K, Ikemoto S, Goto K. Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis. Ann N Y Acad Sci 2002, 965:292-304.
69. Yui K, Ikemoto S, Goto K, Nishijima K, Kato S. Susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis. J Clin Psychopharmacol 2003, 23(5):525-528. 10.1097/01.jcp.0000088919.02635.d7, 14520136.
70. Yui K, Goto K, Ikemoto S. The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence. Ann N Y Acad Sci 2004, 1025:296-306. 10.1196/annals.1316.037, 15542730.
71. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 1986, 396(2):157-198. 10.1016/0165-0173(86)90002-0, 3527341.
72. Strakowski SM, Sax KW, Rosenberg HL, DelBello MP, Adler CM. Human response to repeated low-dose d-amphetamine: evidence for behavioral enhancement and tolerance. Neuropsychopharmacology 2001, 25(4):548-554. 10.1016/S0893-133X(01)00253-6, 11557168.
73. Bartlett E, Hallin A, Chapman B, Angrist B. Selective sensitization to the psychosis-inducing effects of cocaine: a possible marker for addiction relapse vulnerability?. Neuropsychopharmacology 1997, 16(1):77-82. 10.1016/S0893-133X(96)00164-9, 8981391.
74. Chen CK, Lin SK, Sham PC, Ball D, Loh EW, Hsiao CC, et al. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med 2003, 33(8):1407-1414. 10.1017/S0033291703008353, 14672249.
75. Vincent N, Schoobridge J, Ask A, Allsop S, Ali R. Physical and mental health problems in amphetamine users from metropolitan Adelaide, Australia. Drug Alcohol Rev 1998, 17(2):187-195. 10.1080/09595239800186991, 16203484.
76. Sato M. Long-lasting hypersensitivity to methamphetamine following amygdaloid kindling in cats: the relationship between limbic epilepsy and the psychotic state. Biol Psychiatry 1983, 18(5):525-536.
77. Sato M, Chen CC, Akiyama K, Otsuki S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 1983, 18(4):429-440.
78. Myers CS, Halladay AK, Widmer DA, Wagner GC. Neurotoxic effects of amphetamine plus L-DOPA. Prog Neuropsychopharmacol Biol Psychiatry 1999, 23(4):731-740. 10.1016/S0278-5846(99)00031-7, 10390730.
79. Iyo M, Sekine Y, Mori N. Neuromechanism of developing methamphetamine psychosis: a neuroimaging study. Ann N Y Acad Sci 2004, 1025:288-295. 10.1196/annals.1316.036, 15542729.
80. Grace AA. Dopamine system dysregulation by the ventral subiculum as the common pathophysiological basis for schizophrenia psychosis, psychostimulant abuse, and stress. Neurotox Res 2010, 18(3-4):367-376. 2932888, 20143199.
81. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 2000, 97(14):8104-8109. 10.1073/pnas.97.14.8104, 16677, 10884434.
82. Seeman P. All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2 Receptors. CNS Neurosci Ther 2010, 17(2):1755-1759.
83. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987, 91(4):415-433.
84. Tsuang MT, Simpson JC, Kronfol Z. Subtypes of drug abuse with psychosis. Demographic characteristics, clinical features, and family history. Arch Gen Psychiatry 1982, 39(2):141-147. 10.1001/archpsyc.1982.04290020013003, 7065828.
85. Chen CK, Lin SK, Sham PC, Ball D, Loh E, Murray RM. Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Genet B Neuropsychiatr Genet 2005, 136B(1):87-91. 10.1002/ajmg.b.30187, 15892150.
86. McKetin R, Hickey K, Devlin K, Lawrence K. The risk of psychotic symptoms associated with recreational methamphetamine use. Drug Alcohol Rev 2010, 29(4):358-363. 10.1111/j.1465-3362.2009.00160.x, 20636650.
87. Salo R, Leamon MH, Natsuaki Y, Moore C, Waters C, Nordahl TE. Findings of preserved implicit attention in methamphetamine dependent subjects. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(1):217-223. 10.1016/j.pnpbp.2007.08.012, 17870223.
88. Yui K, Ishiguro T, Goto K, Ikemoto S. Precipitating factors in spontaneous recurrence of methamphetamine psychosis. Psychopharmacology (Berl) 1997, 134(3):303-308.
89. Espelin DE, Done AK. Amphetamine poisoning. Effectiveness of chlorpromazine. N Engl J Med 1968, 278(25):1361-1365. 10.1056/NEJM196806202782502, 5650165.
90. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999, 35(1):51-68. 10.1016/S0920-9964(98)00105-4, 9988841.
91. Shoptaw SJ, Kao U, Ling W. Treatment for amphetamine psychosis. Cochrane Database Syst Rev 2009, (1):CD003026.
92. Leelahanaj T, Kongsakon R, Netrakom P. A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thai 2005, 88(Suppl 3):S43-S52.
93. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000, 26(2):441-449. 10.1093/oxfordjournals.schbul.a033464, 10885642.
94. Noordsy DL, O'Keefe C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. J Clin Psychiatry 1999, 60(Suppl 19):47-51.
95. Noordsy DL, O'Keefe C, Mueser KT, Xie H. Six-month outcomes for patients who switched to olanzapine treatment. Psychiatr Serv 2001, 52(4):501-507. 10.1176/appi.ps.52.4.501, 11274497.
96. Foster S, Kessel J, Berman ME, Simpson GM. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 1997, 12(3):175-179. 10.1097/00004850-199705000-00009, 9248875.
97. Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 2005, 1(11 Suppl):5-108.
98. Granado N, Ares-Santos S, Oliva I, O'Shea E, Martin ED, Colado MI, et al. Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol Dis 2011, 42(3):391-403. 10.1016/j.nbd.2011.01.033, 21303698.
99. Hall HV, McPherson SB, Yudko E. Methamphetamine use - Clinical and forensic aspects 2009, New York: CRC Press, Second Edition.
100. Caton CL, Drake RE, Hasin DS, Dominguez B, Shrout PE, Samet S, et al. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Arch Gen Psychiatry 2005, 62(2):137-145. 10.1001/archpsyc.62.2.137, 15699290.
101. Mathias S, Lubman DI, Hides L. Substance-induced psychosis: a diagnostic conundrum. J Clin Psychiatry 2008, 69(3):358-367. 10.4088/JCP.v69n0304, 18278990.
102. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370(9584):319-328. 10.1016/S0140-6736(07)61162-3, 17662880.
103. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002, 325(7374):1199. 10.1136/bmj.325.7374.1199, 135490, 12446534.
104. D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 2009, 259(7):413-431. 10.1007/s00406-009-0024-2, 2864503, 19609589.
105. Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 2003, 71(1):37-48. 10.1016/S0376-8716(03)00064-4, 12821204.
106. D'Souza DC. Cannabinoids and psychosis. Int Rev Neurobiol 2007, 78:289-326.
107. Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, et al. Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry 2012, 169(4):389-396. 10.1176/appi.ajp.2011.10070937, 22193527.
108. Hermens DF, Lubman DI, Ward PB, Naismith SL, Hickie IB. Amphetamine psychosis: a model for studying the onset and course of psychosis. Med J Aust 2009, 190(4 Suppl):S22-S25.